Association between Tumor Necrosis Factor-α and Disease Progression in Patients with Multiple Sclerosis (Q43876866)

reason for preferred rank

27 November 2017

title

Association between Tumor Necrosis Factor-α and Disease Progression in Patients with Multiple Sclerosis (English)

1 reference

https://api.crossref.org/works/10.1056/NEJM199108153250704

10 December 2022

Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1852181

10 December 2022

0 references

M. K. Sharief

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1852181

10 December 2022

R. Hentges

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1852181

10 December 2022

language of work or name

English

0 references

publication date

1 August 1991

1 reference

27 November 2017

15 August 1991

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1852181

full work available at URL

10 December 2022

http://www.nejm.org/doi/pdf/10.1056/NEJM199108153250704

1 reference

https://api.crossref.org/works/10.1056/NEJM199108153250704

The New England Journal of Medicine

10 December 2022

published in

1 reference

27 November 2017

volume

325

1 reference

27 November 2017

issue

7

1 reference

27 November 2017

page(s)

467-472

1 reference

The long march of the cerebrospinal fluid profile indicative of clinical definite multiple sclerosis; and still marching

27 November 2017

cites work

2

1 reference

https://api.crossref.org/works/10.1056/NEJM199108153250704

Multiple Sclerosis as a Disease of Immune Regulation

10 December 2022

3

1 reference

https://api.crossref.org/works/10.1056/NEJM199108153250704

Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions

10 December 2022

4

1 reference

https://api.crossref.org/works/10.1056/NEJM199108153250704

Correlation of interleukin-1 beta and cachectin concentrations in cerebrospinal fluid and outcome from bacterial meningitis

10 December 2022

6

1 reference

https://api.crossref.org/works/10.1056/NEJM199108153250704

Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro

10 December 2022

8

1 reference

https://api.crossref.org/works/10.1056/NEJM199108153250704

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

10 December 2022

9

1 reference

https://api.crossref.org/works/10.1056/NEJM199108153250704

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

10 December 2022

10

1 reference

https://api.crossref.org/works/10.1056/NEJM199108153250704

Histocompatibility determinants in multiple sclerosis, with special reference to clinical course

10 December 2022

11

1 reference

https://api.crossref.org/works/10.1056/NEJM199108153250704

Age at onset, initial symptomatology and the course of multiple sclerosis

10 December 2022

12

1 reference

https://api.crossref.org/works/10.1056/NEJM199108153250704

Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group.

10 December 2022

13

1 reference

https://api.crossref.org/works/10.1056/NEJM199108153250704

Detection of circulating tumor necrosis factor after endotoxin administration.

10 December 2022

14

1 reference

https://api.crossref.org/works/10.1056/NEJM199108153250704

A rapid method for detecting oligoclonal IgG in unconcentrated CSF, by agarose isoelectric focusing, transfer to cellulose nitrate and immunoperoxidase staining

10 December 2022

15

1 reference

https://api.crossref.org/works/10.1056/NEJM199108153250704

Multiple sclerosis: The blood-brain-barrier and the measurement of de novo central nervous system IgG synthesis

10 December 2022

16

1 reference

https://api.crossref.org/works/10.1056/NEJM199108153250704

Calculating confidence intervals for some non-parametric analyses

10 December 2022

18

1 reference

https://api.crossref.org/works/10.1056/NEJM199108153250704

Hypothesis: a role for tumor necrosis factor in immune-mediated demyelination and its relevance to multiple sclerosis

10 December 2022

20

1 reference

https://api.crossref.org/works/10.1056/NEJM199108153250704

Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations?

10 December 2022

21

1 reference

https://api.crossref.org/works/10.1056/NEJM199108153250704

Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. The Multiple Sclerosis Study Group

10 December 2022

22

1 reference

https://api.crossref.org/works/10.1056/NEJM199108153250704

Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

10 December 2022

24

1 reference

https://api.crossref.org/works/10.1056/NEJM199108153250704

Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs

10 December 2022

25

1 reference

https://api.crossref.org/works/10.1056/NEJM199108153250704

Cyclophosphamide in chronic progressive multiple sclerosis. Maintenance vs nonmaintenance therapy

10 December 2022

26

1 reference

https://api.crossref.org/works/10.1056/NEJM199108153250704

Correlation of immunological studies and disease progression in chronic progressive multiple sclerosis

10 December 2022

27

1 reference

https://api.crossref.org/works/10.1056/NEJM199108153250704

A longitudinal study on IL-2, sIL-2R, IL-4 and IFN-γ in multiple sclerosis CSF and serum

10 December 2022

28

1 reference

https://api.crossref.org/works/10.1056/NEJM199108153250704

Tumor necrosis factor alpha/cachectin stimulates eosinophil oxidant production and toxicity towards human endothelium

10 December 2022

29

1 reference

https://api.crossref.org/works/10.1056/NEJM199108153250704

Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation

10 December 2022

30

1 reference

https://api.crossref.org/works/10.1056/NEJM199108153250704

Multiple sclerosis or blood-brain barrier disease

10 December 2022

31

1 reference

https://api.crossref.org/works/10.1056/NEJM199108153250704

Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications

10 December 2022

32

1 reference

https://api.crossref.org/works/10.1056/NEJM199108153250704

Blood-brain barrier damage in acute multiple sclerosis plaques. An immunocytological study

10 December 2022

33

1 reference

https://api.crossref.org/works/10.1056/NEJM199108153250704

Pathology, histochemistry and immunocytochemistry of lesions in acute multiple sclerosis

10 December 2022

34

1 reference

https://api.crossref.org/works/10.1056/NEJM199108153250704

Tumor necrosis factor identified in multiple sclerosis brain

10 December 2022

37

1 reference

https://api.crossref.org/works/10.1056/NEJM199108153250704

Tumor necrosis factor in serum and cerebrospinal fluid of patients with multiple sclerosis

10 December 2022

38

1 reference

https://api.crossref.org/works/10.1056/NEJM199108153250704

Improvement in sensitivity of enzyme-linked immunosorbent assay for tumour necrosis factor

10 December 2022

39

1 reference

https://api.crossref.org/works/10.1056/NEJM199108153250704

Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis

10 December 2022

40

1 reference

https://api.crossref.org/works/10.1056/NEJM199108153250704

Meningococcal septicaemia treated with combined plasmapheresis and leucapheresis or with blood exchange.

10 December 2022

41

1 reference

https://api.crossref.org/works/10.1056/NEJM199108153250704

Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia

10 December 2022

42

1 reference

https://api.crossref.org/works/10.1056/NEJM199108153250704

10 December 2022

Identifiers

1 reference

27 November 2017

1 reference